Floatz logo

ROSOPATAMAB

Head and Neck Cancer

Weill Medical College of Cornell Universitymonoclonal_antibodyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

142 Active assets in the Head and Neck Cancer cohort.

Asset / SponsorPhaseRating
NEPENTHE
Instituto Nacional de Cancer, Brazil
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
ImmunityBio, Inc.
Phase 3BB
LIDOCAINE
Instituto Nacional de Cancer, Brazil
Phase 3BB
Carboplatin
Rapa Therapeutics LLC
Phase 3BB
Cetuximab
Pfizer
Phase 3BB

View all 50 →

Same molecule, other indications

ROSOPATAMAB is also rated in:

prostate cancerDormant
B
Indicative ·
63 / 100
View asset →
Metastatic Prostate CancerDormant
B
Indicative ·
59 / 100
View asset →
prostate neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →